Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Summit Therapeutics (SMMT) Receivables - Other (2018 - 2025)

Summit Therapeutics' Receivables - Other history spans 6 years, with the latest figure at $12000.0 for Q1 2025.

  • For Q1 2025, Receivables - Other changed N/A year-over-year to $12000.0; the TTM value through Mar 2025 reached $12000.0, changed N/A, while the annual FY2021 figure was $574000.0, N/A changed from the prior year.
  • Receivables - Other reached $12000.0 in Q1 2025 per SMMT's latest filing, down from $90000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $1.1 million in Q2 2022 to a low of $12000.0 in Q1 2025.
  • Average Receivables - Other over 4 years is $397833.3, with a median of $322500.0 recorded in 2022.